Newbridge Financial Services Group’s BridgeBio Pharma BBIO Stock Holding History

Newbridge Financial Services Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25	Closed	-$659	–	1167
2023 Q3	$659	Hold	25	–	–	﹤0.01%	1185
2023 Q2	$430	Hold	25	–	–	﹤0.01%	1267
2023 Q1	$415	Hold	25	–	–	﹤0.01%	1331
2022 Q4	$191	Hold	25	–	–	﹤0.01%	1385
2022 Q3	$0	Hold	25	–	–	﹤0.01%	1385
2022 Q2	$0	Hold	25	–	–	﹤0.01%	1366
2022 Q1	$0	Hold	25	–	–	﹤0.01%	1441
2021 Q4	$0	Hold	25	–	–	﹤0.01%	1417
2021 Q3	$1K	Hold	25	–	–	﹤0.01%	1226
2021 Q2	$2K	Hold	25	–	–	﹤0.01%	1255
2021 Q1	$2K	Buy	+25	New	+$1.64K	﹤0.01%	1157

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Newbridge Financial Services Group's BBIO Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 25 shares — an estimated $659 sold.

Newbridge Financial Services Group first reported a position in BBIO in Q1 2021 and held it in 11 quarters. The position peaked at $2K in Q2 2021. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

Newbridge Financial Services Group reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
Newbridge Financial Services Group sold 25 BridgeBio Pharma shares in Q4 2023, an estimated $659.
Newbridge Financial Services Group first reported a position in BridgeBio Pharma in Q1 2021 and held it in 11 quarters.
Newbridge Financial Services Group's BridgeBio Pharma position peaked at $2K in Q2 2021.
247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.